Ever wondered if Arrowhead Pharmaceuticals’ meteoric rise means the best value is behind it, or if there is still room to capitalize? Let’s break down whether now is actually a good time to buy in.
Fintel reports that on November 20, 2025, Goldman Sachs maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with ...
Arrowhead Pharmaceuticals' fair value estimate has recently risen from $47.50 to $55.00 per share, signaling an improved outlook following the FDA approval of Redemplo. This updated price target ...
The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...
Arrowhead Pharmaceuticals faces key FDA decisions, legal challenges, and trial results. Read the latest analysis on the stock ...
Fintel reports that on November 19, 2025, Chardan Capital maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) ...
The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta ...
Pharmaceutical Technology on MSN
Arrowhead nets first commercial win as siRNA drug garners FDA approval
Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.
The Colts are coming off their bye week and the Chiefs have lost two straight. Kansas City is 0-5 in one-possession games.
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. is a better investment based on AAII ...
Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.
Patrick Mahomes and Andy Reid lost 3 in a row to Lou Anarumo's Cincinnati defense. Can Anarumo bring that same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback